Redeye reiterate its Base case valuation of SEK 5 following IDL Biotech’s Q1 report despite a significant sales drop expected in Q2 in the wake of the corona crisis. After speaking with management, we feel a growing conviction that the effect will be temporary and that the growth story will continue once the dust has settle, most likely in Q4.